Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)'s Wayne Paterson tells Proactive about the 30-day follow-up data just in from the company’s flagship heart valve, currently being tested in humans for the first time. The valve solves the problem of younger and more active heart patients who need a valve that performs better and lasts longer, and Paterson says these latest clinical results meet and exceed the company’s expectations.